Table 1.
Half-maximal inhibitory concentration (IC50) determined in the cell viability and proliferation assay (MTT) assay and Trypan blue exclusion testing of human glioblastoma U251 cells treated for 24 h and 48 h with the Les-3288, doxorubicine (Dox), and temozolomide (TMZ)
IC50 μg/mL | MTT assay |
Trypan blue testing |
||
---|---|---|---|---|
24 h | 48 h | 24 h | 48 h | |
Dox |
0.96 |
0.41 |
0.88 |
0.13 |
Les-3288 |
0.74 |
0.31 |
0.63 |
0.22 |
TMZ | 50.26 | 24.43 | 50.02 | 34.00 |